BRPI0807601A2 - Método para a identificação de risco com relação a distúrbio da tireoide. - Google Patents

Método para a identificação de risco com relação a distúrbio da tireoide.

Info

Publication number
BRPI0807601A2
BRPI0807601A2 BRPI0807601-4A2A BRPI0807601A BRPI0807601A2 BR PI0807601 A2 BRPI0807601 A2 BR PI0807601A2 BR PI0807601 A BRPI0807601 A BR PI0807601A BR PI0807601 A2 BRPI0807601 A2 BR PI0807601A2
Authority
BR
Brazil
Prior art keywords
identification method
risk identification
thyroid disorder
thyroid
disorder
Prior art date
Application number
BRPI0807601-4A2A
Other languages
English (en)
Inventor
David H Margolin
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BRPI0807601A2 publication Critical patent/BRPI0807601A2/pt
Publication of BRPI0807601B1 publication Critical patent/BRPI0807601B1/pt
Publication of BRPI0807601B8 publication Critical patent/BRPI0807601B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70592—CD52
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/046—Thyroid disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI0807601A 2007-02-16 2008-02-15 método para identificação de um paciente que esteja em risco com relação ao desenvolvimento de um distúrbio na tireoide e uso de um agente depletivo de linfócitos BRPI0807601B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90173207P 2007-02-16 2007-02-16
US60/901,732 2007-02-16
PCT/US2008/002047 WO2008103292A1 (en) 2007-02-16 2008-02-15 Method of identifying risk for thyroid disorder

Publications (3)

Publication Number Publication Date
BRPI0807601A2 true BRPI0807601A2 (pt) 2014-05-06
BRPI0807601B1 BRPI0807601B1 (pt) 2021-02-23
BRPI0807601B8 BRPI0807601B8 (pt) 2021-07-27

Family

ID=39434244

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807601A BRPI0807601B8 (pt) 2007-02-16 2008-02-15 método para identificação de um paciente que esteja em risco com relação ao desenvolvimento de um distúrbio na tireoide e uso de um agente depletivo de linfócitos

Country Status (22)

Country Link
US (3) US20100136587A1 (pt)
EP (2) EP2130044B1 (pt)
JP (2) JP5662684B2 (pt)
CN (2) CN108303546B (pt)
AU (1) AU2008219097B2 (pt)
BR (1) BRPI0807601B8 (pt)
CA (1) CA2678199A1 (pt)
CY (1) CY1118663T1 (pt)
DK (1) DK2130044T3 (pt)
ES (1) ES2612558T3 (pt)
HK (1) HK1257419A1 (pt)
HR (1) HRP20170121T1 (pt)
HU (1) HUE031421T2 (pt)
IL (2) IL200314A (pt)
LT (1) LT2130044T (pt)
MX (1) MX2009008642A (pt)
PL (1) PL2130044T3 (pt)
PT (1) PT2130044T (pt)
RS (1) RS55636B1 (pt)
RU (1) RU2013120485A (pt)
SI (1) SI2130044T1 (pt)
WO (1) WO2008103292A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
FR2934129B1 (fr) * 2008-07-24 2014-05-02 Oreal Procede de traitement cosmetique.
AU2009292905A1 (en) * 2008-09-19 2010-03-25 Lineagen, Inc. Methods for identification and prediction of multiple sclerosis disease and therapy response
CN106257288A (zh) * 2016-08-15 2016-12-28 余洋 一种血清TPOAb IgG4水平检测方法
JP6992200B2 (ja) 2018-07-02 2022-02-03 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド 新規甲状腺ペルオキシダーゼ自己抗体イムノアッセイ
KR102469743B1 (ko) * 2020-06-10 2022-11-22 주식회사 타이로스코프 약물 복용에 따른 갑상선 기능 모니터링 방법, 이를 수행하는 모니터링 서버 및 사용자 단말
EP4001919A1 (en) * 2020-11-13 2022-05-25 Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal Predictive biomarkers of autoimmunity in patients treated with alemtuzumab

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB2265713A (en) * 1992-05-16 1993-10-06 R S R Limited Assay for autoantibodies against thyroglobulin or thyroid peroxidase
DE19710211C2 (de) * 1997-03-12 1999-12-16 Brahms Diagnostica Gmbh Verfahren zur Bestimmung von Schilddrüsen-Autoantikörpern
GB9823397D0 (en) * 1998-10-27 1998-12-23 Rsr Ltd Assays for thyroid autoantibodies
US20060130161A1 (en) * 2004-10-12 2006-06-15 Carantech, Inc. Animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and diabetes
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)

Also Published As

Publication number Publication date
CY1118663T1 (el) 2017-07-12
PL2130044T3 (pl) 2017-04-28
US20100136587A1 (en) 2010-06-03
SI2130044T1 (sl) 2017-03-31
RU2013120485A (ru) 2014-11-20
CN108303546B (zh) 2023-01-03
CN108303546A (zh) 2018-07-20
ES2612558T3 (es) 2017-05-17
IL242391A (en) 2017-09-28
RU2009134313A (ru) 2011-03-27
MX2009008642A (es) 2009-10-20
HUE031421T2 (hu) 2017-07-28
CN101657721B (zh) 2018-02-23
WO2008103292A1 (en) 2008-08-28
PT2130044T (pt) 2017-02-03
JP5662684B2 (ja) 2015-02-04
RS55636B1 (sr) 2017-06-30
JP6058585B2 (ja) 2017-01-11
EP2130044A1 (en) 2009-12-09
EP2538217A1 (en) 2012-12-26
JP2014149313A (ja) 2014-08-21
IL200314A (en) 2015-11-30
US20170307629A1 (en) 2017-10-26
DK2130044T3 (en) 2017-02-06
US9664688B2 (en) 2017-05-30
LT2130044T (lt) 2017-02-10
US20130095507A1 (en) 2013-04-18
IL200314A0 (en) 2010-04-29
HRP20170121T1 (hr) 2017-03-24
EP2130044B1 (en) 2016-10-26
CN101657721A (zh) 2010-02-24
AU2008219097A1 (en) 2008-08-28
BRPI0807601B1 (pt) 2021-02-23
BRPI0807601B8 (pt) 2021-07-27
AU2008219097B2 (en) 2011-06-23
JP2010519512A (ja) 2010-06-03
US10648986B2 (en) 2020-05-12
CA2678199A1 (en) 2008-08-28
HK1257419A1 (zh) 2019-10-18

Similar Documents

Publication Publication Date Title
BRPI0822723A2 (pt) Método para fabricar um cartão de transação, e, cartão de transação
BRPI0812508A2 (pt) Dispositivo e processo para controlar um dispositivo de freio.
BRPI0923790A2 (pt) Método para calcular um sistema, por exemplo um sistema óptico
BRPI0908233A2 (pt) Leitora adaptada para um computador portátil
BRPI0818571A2 (pt) Cartucho para um biossensor, e, método para fabricar um cartucho
BRPI0909788A2 (pt) método para fabricar um dispositivo emissor de luz, e, dispositivo emissor de luz.
BRPI0811763A2 (pt) Método para completar uma transação, meio legível por computador, servidor, e, telefone
AP2011005598A0 (en) Bearing information on a card.
BRPI0906327A2 (pt) Folha de registro e método para fabricar folha de registro.
BRPI0806558A2 (pt) Método para a transmissão e recebimento de informações de sistema.
BRPI0909395A2 (pt) método para a obtenção de um granulação de poliamida aromática
BRPI0813251A2 (pt) Máquina e método para rotular recipientes.
BRPI0821729A2 (pt) Tapete, revestimento de tapete e método para fabricar um tapete
BRPI0910441A2 (pt) sistema de comunicação para uma instalação de extração de hidrocarbonato
BRPI0811719A2 (pt) Sistema para a fixação de um trilho
BRPI1007504A2 (pt) método para pré-carregar um sistema de catamarã, e, sistema de catamarã.
BRPI0807601A2 (pt) Método para a identificação de risco com relação a distúrbio da tireoide.
BRPI0921882A2 (pt) processo para fabricar um composto.
BR112012002861A2 (pt) método e dispositivo para a provisão de informações complementares
HK1129759A1 (en) Manufacturing method for rfid tags rfid
BRPI0818898A2 (pt) Pacote para um dispositivo de distribuição.
BRPI0819448A2 (pt) Método para transações seguras
BRPI0906989A2 (pt) Método para a identificação da pressão do ponto de borbulhamento
BRPI0823029A2 (pt) Conjunto, e, método para fazer um conjunto.
BRPI0923417A2 (pt) máquina para rotulagem.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/02/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO